Impact of Covid-19 on disruption of oncology clinical trials

Companies and organisations continue to report clinical trial disruptions, which includes delayed initiation, enrollment suspension and slow enrollment due to the Covid-19 pandemic.

By GlobalData Healthcare

Companies and organisations continue to report clinical trial disruptions, which includes delayed initiation, enrollment suspension and slow enrollment due to the Covid-19 pandemic. The total number of clinical trials disrupted showed slow enrollment was the top reason, followed by enrollment suspension and lastly delayed initiation (Figure 1).

Free Case Study

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges

by Suvoda

Enter your details here to receive your free Case Study.

By clicking the Download Free Case Study button, you accept the terms and conditions and acknowledge that your data will be used as described in the Suvoda privacy policy By downloading this Case Study, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

When analysing these disrupted trials by therapy area, oncology leads all others in disrupted clinical trials due to the Covid-19 pandemic. Phase II has the most oncology disrupted clinical trials, followed by Phase I and then Phase III. A further breakdown can be seen in Figure 2. Furthermore, when looking at the region, North America outnumbered all other regions in disrupted clinical trials in both multinational and single-country trials. Europe was second in both, followed by Asia-Pacific, the Middle East and Africa and South and Central America (Figure 3). North America far exceeds all other regions when it comes to single-country disrupted clinical trials.